CS/HB 451

1	A bill to be entitled
2	An act relating to nonopioid alternatives; amending s.
3	456.44, F.S.; providing legislative intent; requiring
4	the Department of Health to develop and publish on its
5	website an educational pamphlet regarding the use of
6	nonopioid alternatives for the treatment of pain;
7	requiring the pamphlet to include specified
8	information, including the advantages and
9	disadvantages of the use of such alternatives;
10	providing requirements for health care practitioners;
11	providing an effective date.
12	
13	Be It Enacted by the Legislature of the State of Florida:
14	
15	Section 1. Subsection (7) is added to section 456.44,
16	Florida Statutes, to read:
17	456.44 Controlled substance prescribing
18	(7) NONOPIOID ALTERNATIVES
19	(a) The Legislature finds that every competent adult has
20	the fundamental right of self-determination regarding decisions
21	pertaining to his or her own health, including the right to
22	refuse an opioid drug listed as a Schedule II controlled
23	substance in s. 893.03 or 21 U.S.C. s. 812.
24	(b) The department shall develop and publish on its
25	website an educational pamphlet regarding the use of nonopioid

Page 1 of 2

CODING: Words stricken are deletions; words underlined are additions.

2019

CS/HB 451

2019

26	alternatives for the treatment of pain. The pamphlet shall, at a
27	minimum, include:
28	1. Information on available nonopioid alternatives for the
29	treatment of pain, including nonopioid medicinal drugs or drug
30	products and nonpharmacological therapies.
31	2. The advantages and disadvantages of the use of
32	nonopioid alternatives.
33	(c) Except in the provision of emergency services and
34	care, as defined in s. 395.002, before providing medical
35	treatment or anesthesia or prescribing an opioid drug listed as
36	a Schedule II controlled substance in s. 893.03 or 21 U.S.C. s.
37	812 for the treatment of pain, a health care practitioner must:
38	1. Inform the patient of available nonopioid alternatives
39	for the treatment of pain, including nonopioid medicinal drugs
40	or drug products, physical therapy, occupational therapy, or any
41	other appropriate therapy.
42	2. Discuss the advantages and disadvantages of the use of
43	nonopioid alternatives, including whether the patient is at a
44	high risk of, or has a history of, controlled substance abuse or
45	misuse and the patient's personal preferences.
46	3. Provide the patient with the educational pamphlet
47	described in paragraph (b).
48	4. Document the nonopioid alternatives considered in the
49	patient's record.
50	Section 2. This act shall take effect July 1, 2019.
	Page 2 of 2

CODING: Words stricken are deletions; words underlined are additions.